What Does Ocugen Do?

Total employees79
HeadquartersMalvern
Founded2013

Ocugen, Inc. is a U.S.-based biotechnology company dedicated to the discovery, development, and commercialization of innovative gene and cell therapies, biologics, and vaccines. Their primary focus is on addressing unmet medical needs in rare and underserved eye diseases, as well as developing vaccines for infectious diseases. Ocugen aims to leverage its modifier gene therapy platform and other proprietary technologies to deliver transformative treatments to patients worldwide.

Where Is Ocugen's Headquarters?

HQ Function

Ocugen's headquarters in Malvern serves as the central hub for its corporate administration, research and development leadership, clinical operations management, and strategic business development activities.

Notable Features:

Located within the Great Valley corporate center, a well-known hub for life sciences and technology companies, providing a modern and collaborative environment. Proximity to Philadelphia's rich biotech ecosystem.

Work Culture:

Ocugen likely fosters a science-driven, innovative, and patient-focused work culture. Emphasis is placed on collaboration, scientific rigor, and a commitment to advancing medical breakthroughs for diseases with high unmet needs.

HQ Significance:

The Malvern headquarters is critical for coordinating Ocugen's global clinical trials, managing regulatory affairs with bodies like the FDA, and steering the company's overall strategic direction and partnerships.

Values Reflected in HQ: The headquarters' location in a prominent biotech cluster reflects Ocugen's commitment to innovation, access to specialized talent, and collaboration within the life sciences community.

Location:

Ocugen's global presence is primarily characterized by its international clinical trial operations conducted across multiple countries, engagement with global regulatory authorities for its product candidates, and strategic collaborations for development and potential commercialization. While its physical corporate presence is centered in the U.S., its operational and strategic reach is international, particularly in advancing its gene therapy and vaccine programs.

Street Address:

263 Great Valley Parkway

City:

Malvern

State/Province:

PA

Country:

USA

Where Else Does Ocugen Operate Around the World?

No additional office locations available.

Buying Intent Signals for Ocugen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Ocugen? Meet the Executive Team

As of April 2025, Ocugen' leadership includes:

Shankar Musunuri, PhD, MBA - Chairman, Chief Executive Officer, and Co-Founder
Quan A. Vu - Chief Financial Officer & Chief Business Officer
Arun Upadhyay, PhD - Chief Scientific Officer, Head of R&D
Huma Qamar, MD, MPH - Chief Medical Officer
Jessica Crespo, CPA - Chief Accounting Officer & Senior Vice President, Finance
Chris R. Horrell, JD - Senior Vice President, General Counsel
Syed F. Rabbani - Senior Vice President, Quality
Phil Galluppi - Senior Vice President, Technical Operations
Peter Chang, MD - Senior Vice President, Clinical Development
Kelly L. Bain - Senior Vice President, Human Resources

Who's Investing in Ocugen?

Ocugen has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock Inc.
State Street Corporation
Geode Capital Management, LLC
Morgan Stanley

What Leadership Changes Has Ocugen Seen Recently?

Hire2
Exits1

Over the past 12 months, Ocugen has strengthened its leadership team with key appointments, particularly in medical and clinical development roles, including a new Chief Medical Officer and a Senior Vice President of Clinical Development. There was also a transition in the Chief Medical Officer position.

Departures

Dr. Robert Hopkins, Dr. Robert Hopkins transitioned from his role as Chief Medical Officer.

New Appointments:

Dr. Huma Qamar, Dr. Huma Qamar appointed as new Chief Medical Officer.
Peter Chang, MD, Peter Chang, MD, appointed as new Senior Vice President, Clinical Development.

What Technology (Tech Stack) Is Used byOcugen?

Discover the tools Ocugen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Ocugen Email Formats and Examples

Ocugen, Inc. typically uses a standard corporate email format. The most commonly observed pattern is [first name].[last name]@ocugen.com. Other variations might exist but this is a strong primary pattern.

[first].[last]@ocugen.com

Format

jane.doe@ocugen.com

Example

75%

Success rate

What's the Latest News About Ocugen?

Ocugen, Inc. (GlobeNewswire)May 9, 2024

Ocugen, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Ocugen announced its financial results for Q1 2024, highlighting progress in its pipeline including its OCU400 gene therapy for retinitis pigmentosa and OCU200 for diabetic macular edema. The company also provided updates on its regenerative cell therapy and vaccine programs....more

Ocugen, Inc. (GlobeNewswire)April 25, 2024

Ocugen, Inc. Announces Positive Top-line Results for OCU200 Phase 1 Clinical Trial in Patients with Diabetic Macular Edema (DME)

Ocugen reported positive top-line data from its Phase 1 clinical trial of OCU200, a novel biologic product candidate for treating Diabetic Macular Edema (DME). The study met its primary safety and tolerability endpoints....more

Ocugen, Inc. (GlobeNewswire)March 26, 2024

Ocugen, Inc. Receives U.S. FDA Orphan Drug Designation for OCU410ST—Modifier Gene Therapy Candidate—for the Treatment of Stargardt Disease

Ocugen announced that the U.S. FDA granted Orphan Drug Designation (ODD) for OCU410ST (AAV-hRORA), its modifier gene therapy candidate for the treatment of Stargardt disease, a rare genetic eye disorder....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Ocugen, are just a search away.